ASCO26: Julia Rotow, MD, Silevertinib in Lung Cancer - Quiz - MDSpire

ASCO26: Julia Rotow, MD, Silevertinib in Lung Cancer

Dana-Farber Cancer Institute's Dr. Julia Rotow reported on a study looking at silevertinib, with data showing it may offer a new first-line option for hard-to-treat EGFR non-small cell lung cancer variants, with encouraging brain activity and manageable side effects.

  • July 1, 2026

Share

Original Source(s)

ASCO26: Julia Rotow, MD, Silevertinib in Lung Cancer

  • July 1, 2026

Related Content

Comparison between germline and somatic loss-of-function RNF43 mutations reveals different genotype-phenotype associations and provides insights into the genetic mechanisms of colorectal tumourigenesis

Multimodal imaging features of primary breast epithelial–myoepithelial carcinoma: a case report and literature review

Case report: Beyond arrhythmia: STAR-inspired single-fraction cardiac radioablation for Ewing sarcoma metastasis